Is There a Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?
| Autor: | Lei Zhao, Meng Zhong Liu, Li Ru He, Shi Liang Liu, Qiao Qiao Li, Jing Xian Shen, Peng Zhang, Mian Xi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Male medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Aging and Cancer Cancer Treatment lcsh:Medicine Radiation Therapy Disease-Free Survival Internal medicine medicine Carcinoma Medicine and Health Sciences Humans lcsh:Science Aged Retrospective Studies Geriatrics Aged 80 and over Multidisciplinary business.industry Cancer Risk Factors lcsh:R Retrospective cohort study Chemoradiotherapy Esophageal cancer medicine.disease Radiation therapy Fluorouracil Carcinoma Squamous Cell T-stage lcsh:Q Female Esophageal Squamous Cell Carcinoma business medicine.drug Research Article |
| Zdroj: | PLoS ONE PLoS ONE, Vol 9, Iss 8, p e105270 (2014) |
| ISSN: | 1932-6203 |
| Popis: | Background and purpose The benefit of concurrent chemoradiotherapy (CCRT) in elderly patients with inoperable esophageal squamous cell carcinoma (SCC) is controversial. This study aimed to assess the efficiency and safety of CCRT in elderly thoracic esophageal cancer patients. Methods and materials Between January 2002 and December 2011, 128 patients aged 65 years or older treated with CCRT or radiotherapy (RT) alone for inoperable thoracic esophageal SCC were analyzed retrospectively (RT alone, n = 55; CCRT, n = 73). Results No treatment-related deaths occurred and no patients experienced any acute grade 4 non-hematologic toxicities. Patients treated with CCRT developed more severe acute toxicities than patients who received RT alone. The 3-year overall survival (OS) rate was 36.1% for CCRT compared with 28.5% following RT alone (p = 0.008). Multivariate analysis identified T stage and treatment modality as independent prognostic factors for survival. Further analysis revealed that survival was significantly better in the CCRT group than in the RT alone group for patients ≤ 72 years. Nevertheless, the CCRT group had a similar OS to the RT group for patients > 72 years. Conclusion Our results suggest that elderly patients with inoperable thoracic esophageal SCC could benefit from CCRT, without major toxicities. However, for patients older than 72 years, CCRT is not superior to RT alone in terms of survival benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|